U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are ction of information unless it contains a valid OMB control number

	Application Number		105//814	
	Filing Date		2006-04-28	
	First Named Inventor	Judy	Lieberman	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1635	
not for dabiniosion and or or it may	Examiner Name			
	Attorney Docket Numb	er	033393-055222	

U.S. PATENTS Pages.Columns.Lines where Examiner Cite Kind Name of Patentee or Applicant Patent Number Issue Date Relevant Passages or Relevant Initial* Code1 of cited Document Nο Figures Appear 6228642 R1 2001-05-08 Raker et al If you wish to add additional U.S. Patent citation information please click the Add button. Add U.S. PATENT APPLICATION PUBLICATIONS Remove Pages.Columns.Lines where Evaminer Cite Kind Publication Name of Patentee or Applicant Publication Number Relevant Passages or Relevant Initial* No Code¹ Date of cited Document Figures Appear 1 If you wish to add additional U.S. Published Application citation information please click the Add button Remove FOREIGN PATENT DOCUMENTS Pages.Columns.Lines Name of Patentee or Everniner Cite Kind Publication where Relevant Foreign Document Country Applicant of cited T5 Initial* No Number3 Code2 i Code4 Date Passages or Relevant Document Figures Appear 1 If you wish to add additional Foreign Patent Document citation information please click the Add button Add Remove NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Evaminer Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), T5 Initials* No publisher, city and/or country where published.

1	ASHKENAZI, A. and DIXIT, V.M. Science 281:1305-1308 (1998)	
2	CHIU & RANA, RNA 9:1034-1048 (2003)	
3	DEL ZOPPO, G.J., K.M.A. Welch, L.R. Caplan, D.J. Reis, et al., (Eds.) pp.217-220 Academic Press, San Diego (1997)	
4	FLOYD & CARNEY, Ann. Neurol. 32:S22-S27 (1992)	
5	GREEN, D.R. and EVAN, G.I. Cancer Cell 1:19-30 (2002)	
6	HAMADA et al., Antisense Nucleic Acid Drug Dev. 12:301-309 (2002)	
7	HERWEJER & WOLFF, Gene Therapy 10:453-458 (2003)	
8	HEYMAN et al., Curr. Opin.Crit. Care. 8(6):526-34 (2002)	
9	JACKSON et al., Nat. Biolechnol. 21(6):635-637 (2003)	
10	LIU, K.D., Crit. Care Med. 31(8)(Suppl.):SS72-SS81 (2003)	
11	LEE et al., Am. J. Physiol. Heart Cicr. Physiol. 284:1456-1463 (2003)	

	12	LEWIS et al., Nature Genetics 32:107-108 (2002)	
	13	MARUYAMA et al., J. Gene. Med. 4:333-341 (2002)	
	14	MARUYAMA et al., Hum. Gene Ther. 13:455-468 (2002)	
	15	MATTSON, M.P. Nat. Rev. Mol. Cell. Biol. 1:120-128 (2002)	
	16	MCCAFFREY et al., Nature 418:38-39 (2002)	
	17	MENÈ et al., J. Nephrol. 16:186-195 (2003)	
	18	MEIER, P., et al., Nature 407.796-801 (2000)	
	19	MOGI et al., Lab. Invest. 81(2):177-184 (2001)	
	20	NAGATA & SUDA, Immunology Today 16(1):39-43 (1995)	
	21	NANSEN et al., Blood 99(4):1237-1245 (2002)	
	22	NOGAE et al. J. Am. Soc. Nephrol. 9(4):620-631 (1998)	П

	23	ORTIZ et al , Current Drug Targets - Immune, Endocrine & Metabolic Disorders 2:181-192 (2002)	
	24	PASCHEN, W., J. Cereb. Blood Flow Metab. 23(7):773-779 (2003)	
	25	PRAKASH et al., Ren. Fait. 25(2):225-233 (2003)	
	26	RATHMELL, J.C. and THOMPSON, C.B. Cell 109 (Suppl.): S97-S107 (2002)	
	27	REITER et al., Ann. N.Y. Acad. Sci. 983:35-47 (2003)	
	28	ROWE, P.M., Glimmers of clinical relevance for Fas (1996) Lancet, 347: 1398	
	29	SATA & WALSH, J. Biol. Chem. 273(50):33103-33106 (1998)	
	30	SCAFFIDI et al., J. Biol. Chem. 274(3):1541-1548 (1999)	
	31	SLEDZ et al., Nat. Cell Biol. 5(9):834-839 (2003)	
	32	SONG et al., Nat. Med. 9(3):347-351 (2003)	
	33	SØRENSEN, Dag R. et al., J. Mol. Biol.; 327:761-766 (2003)	П

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10577814
Filing Date		2006-04-28
First Named Inventor Judy		Lieberman
Art Unit		1635
Examiner Name		
Attorney Docket Number		033393-055222

	34	TEOH & FARRELL, J. Gastroenterol. Hepatol. 18:891-902 (2003)	
	35	THADHANI et al., N. Engl. J. Med. 334:1448-60 (1996)	
	36	VAUX, D.L. and KORSMEYER, S.J. Cell 96:245-254 (1999)	
	37	VERMUELEN, K., et al. Cell Proif. 36:165-175 (2003)	
	38	WALL, Nathan R. et al., The Lancet 362:1401-1403 (2003)	
	39	WATANABE-FUKUNAGA, R., et al., J. Immunol., 148:1274-1279 (1992)	
	40	Z-IANG et al., Hum. Gene Ther. 10:1735-1737 (1999)	
	41	ZHANG et al., J. Biol. Chem. 277(40):37430-37438 (2002)	
	42	ZÖRNIG, M., et al., Biochim. Biophys. Acta 1551:F1-F37 (2001)	
If you wish to add additional non-patent literature document citation information please click the Add button Add			

EXAMINER SIGNATURE

Examiner Signature

Date Considered

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

	Application Number		10577814
	Filing Date		2006-04-28
INFORMATION DISCLOSURE	First Named Inventor	Judy	Lieberman
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1635
(Not for Submission under or or it issue	Examiner Name		
	Attorney Docket Numb	er	033393-055222

See First Codes of USPTO Planto Documents at view, USPTO, DOV or MPEP D01.04. * Exter difficie that issued the document, by the two bilder code (VIPO) Standard ST3.3.* * Explaneses paint documents, the includation of the paint of the improve must precise the senial number of the paint document of the paint of the pa